RADICAVA ORS® (edaravone) offers patients an oral option that's formulated to fit their life's routines.1
FDA-APPROVED & AVAILABLE
RADICAVA® (edaravone) helps slow the loss of physical function in patients with ALS
For Their Moments
Big and Small
Proven Efficacy Now
in Oral Form
33% less change in ALSFRS-R from baseline vs placebo at 24 weeks.1,3
Flexible Administration with Oral Dosing
5 mL dose administered in minutes, not hours, as well as an IV option.1
Starting Patients & Cost Support Options
Review steps to beginning or transitioning to oral treatment that can fit into their daily routine.1
The JourneyMate Support Program™ helps to give patients understanding, answers, and resources to supplement what their doctor provides. Experienced program team members are trained to address patient educational needs and provide them with personalized answers and resources for living with ALS.
ALS=Amyotrophic lateral sclerosis.
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of September 2022. Not independently verified. Return to content
bDays of therapy based on number of RADICAVA ORS® and RADICAVA® IV cartons sold as of September 2022. Each carton represents a day’s supply of therapy. Return to content
References: 1. RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022. 2. Data on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc. 3. Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512.